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Purpose: Usher syndrome is an autosomal recessive disorder characterized by hearing and vision loss. Usher syndrome
is divided into three clinical subclasses (type 1, type 2, and type 3), which differ in terms of the severity and progression
of hearing loss and the presence or absence of vestibular symptoms. Usher syndrome is defined by significant genetic
heterogeneity, with at least 12 distinct loci described and 9 genes identified. This study aims to provide a molecular
epidemiology report of Usher syndrome in Italy.
Methods: Molecular data have been obtained on 75 unrelated Italian patients using the most up-to date technology
available for the screening of Usher syndrome gene mutations, i.e., the genotyping microarray developed by Asper Biotech
(Tartu, Estonia), which simultaneously investigates 612 different marker positions using the well established arrayed
primer extension methodology (APEX).
Results: Using this method, we found that 12% of cases (9 out of 75) harbored homozygous or compound heterozygous
mutations in the gene positions analyzed, whereas 20% (15 out of 75) of the patients were characterized by the presence
of only one mutated allele based on the positions analyzed. One patient was found to be compound heterozygous for
mutations in two different genes and this represents an example of possible digenic inheritance in Usher syndrome. A
total of 66.6% of cases (50 out of 75) were found to be completely negative for the presence of Usher syndrome gene
mutations in the detected positions. Mutations detected by the array were confirmed by direct sequencing.
Conclusions: These findings highlight the efficacy of the APEX-based genotyping approach in the molecular assessment
of Usher patients, suggesting the presence of alleles not yet identified and/or the involvement of additional putative genes
that may account for the pathogenesis of Usher syndrome.
Usher  syndrome  represents  a  group  of  recessively
inherited disorders characterized by deafness and vision loss
and, sometimes, by vestibular areflexia. Usher syndrome is
traditionally subdivided into three clinical subclasses (type 1,
type 2, and type 3). The subtypes are differentiated by the
severity and progression of hearing loss and by the presence
or absence of vestibular symptoms, with visual impairment
resulting from retinitis pigmentosa (RP) [1] being common to
all three subtypes. Usher syndrome shows significant genetic
and clinical heterogeneity, and at least 12 distinct loci and 9
genes have been identiﬁed. Although still used in clinical
settings, the above mentioned Usher syndrome classification
has been challenged by the recent description of many atypical
clinical  types.  Usher  syndrome  type  1  patients  are
characterized  by  the  presence  of  congenital,  profound
deafness,  vestibular  dysfunction,  and  prepubertal  onset  of
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progressive RP [2,3]. Usher syndrome type 1 is the most
severe form of Usher syndrome. This form accounts for 30%–
40% of Usher syndrome cases [3-5]. To date, seven genetic
loci  for  Usher  syndrome  type  1  (USH1B–H)  have  been
mapped to chromosomes 11q13.5, 11p15.1, 10q22.1, 21q21,
10q21-q22,  17q24-q25,  and15q22-q23.  Five  of  the
corresponding genes have been identified: 1) the actin-based
motor protein myosin VIIa (MYO7A,USH1B) [6,7], the most
common  Usher  syndrome  type  1  genetic  subtype,  which
accounts for 30%–50% of Usher syndrome type 1 cases in the
UK  and  the  USA  [8,9];  2)  two  cadherin-related  proteins,
namely otocadherin or cadherin 23 (CDH23,USH1D) [10,
11],  and  protocadherin  15  (PCDH15,USH1F)  [12,13],
respectively, representing the second and third most frequent
causes of Usher syndrome type 1, and accounting for 10%–
35% (CDH23) [3-5] and 11% (PCDH15) of Usher syndrome
type 1 cases in both the UK and USA; 3) the last two Usher
syndrome type 1 genes, which encode two scaffold proteins,
harmonin (USH1C) [1,14] and sans (USH1G) [15].
Usher syndrome type 2 is less severe than type 1 and is
characterized  by  congenital  moderate-to-  severe  deafness,
with a high-frequency sloping configuration. Owing to an
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1662overlap in the clinical appearance of the visual symptoms in
types 1 and 2, due to considerable variation in the age of onset,
these symptoms are not considered reliable predictors of the
type of Usher syndrome in individual cases [2,3,16]. Three
genetic loci have been reported so far in Usher syndrome type
2 (USH2A,USH2C, and USH2D). The corresponding genes
have  been  identified.  Mutations  in  the  USH2A  gene  on
chromosome  1q41,  which  encode  usherin,  are  the  most
common  mutations  and  account  for  up  to  85%  of  Usher
syndrome type 2 cases [17,18]. The protein encoded by the
VLGRI [19] gene at the USH2C locus is a member of the
serpentine G-protein coupled receptor superfamily. Defects in
the Whirlin gene, a PDZ (post-synaptic density, disc-large,
Zo-1 protein domains) domain-containing scaffold protein,
are  responsible  for  both  Usher  syndrome  type  2  and
nonsyndromic  hearing  loss  (DFNB31)  [20].  Mutations  in
USH2C and USH2D are rare [19,21].
Usher syndrome type 3 is characterized by variable onset
of progressive hearing loss, variable onset of RP, and variable
impairment of vestibular function [22]. Usher syndrome type
3  is  caused  by  mutations  in  the  USH3A  (clarin-1)  gene,
mapped to 3q21-q25 [23,24]. Usher syndrome type 3 is not as
common as Usher syndrome type 1 and Usher syndrome type
2, with a prevalence of 2%–4% in all Usher syndrome cases.
Comprehensive  molecular  diagnostics  for  Usher
syndrome has been hampered both by genetic heterogeneity
and the large number of exons for most of the Usher genes.
The five Usher syndrome type 1 genes collectively contain
179 protein-coding exons, the two Usher syndrome type 2
genes  comprise  162  protein-coding  exons,  and  the  Usher
syndrome type 3 gene USH3A has six protein-coding exons,
some  of  which  are  alternatively  spliced  (UCSC  Human
Genome Browser). Thus far, large-scale mutation screening
has been performed using single-strand conformation analysis
and  denaturing  gradient  gel  electrophoresis,  with  the
subsequent  sequence  analysis  of  fragments  displaying  an
aberrant  migration  pattern.  For  routine  analysis,  these
techniques  are  both  time  consuming  and  expensive.
Microarray technology previously used for mutation analysis
of the ATP-binding cassette, sub-family A (ABC1), member
4 (ABCA4) gene in patients with either autosomal recessive
Stargardt disease or autosomal recessive cone-rod dystrophy,
as  well  as  for  more  than  ten  genes  implicated  in  Leber
congenital amaurosis (LCA), can also be a useful tool for the
identification of mutations in patients with Usher syndrome.
Inherent to the arrayed primer extension (APEX) is that it only
detects established mutations and, its efficiency is, therefore,
highly dependent on the extent of earlier mutation analysis
efforts. We report on molecular epidemiology data obtained
by analyzing the largest set of Italian Usher cases (75 patients)
ever  collected,  using  the  Usher  microarray  developed  by
Asper Biotech, which detects 612 mutations of the nine genes
involved.
METHODS
Sample selection: A total of 75 patients with Usher Syndrome
recruited  from  several  Italian  centers  (Medical  Genetics,
IRCCS  Burlo  Garofolo-Children  Hospital,  Trieste,  Italy;
Audiology, University of Ferrara, Ferrara, Italy; Department
of  Ophthalmology  of  the  Second  University  of  Naples,
Napoli, Italy); among these, 7 patients were Usher syndrome
type 1, 39 were Usher syndrome type 2, and 29 could not be
classified. The patients underwent a general screening visit
that included a basic ophthalmic consultation, central visual
acuity (CVA), Goldman visual field (GVF), fundus oculi,
standard electroretinography (ERG), and a series of periodic
control visits. The patients also provided a detailed medical
history  and  underwent  genetic  counseling  to  identify
hereditary patterns. Each patient underwent a complete ear,
nose  and  throat  (ENT)  and  audio-vestibular  examination,
including otomicroscopic examination, audiometry, and an
auditory brainstem response (ABR) for threshold assessment
of patients less than 5 years of age. The degree of hearing loss
was evaluated for frequencies 0.25–8,000 Hz. We defined
mild hearing loss as a loss of 45 dB, moderate loss as a loss
of 46–70 dB, severe loss as a loss of 71–90 dB, and profound
hearing loss as a loss >90 dB, according to American speech-
language-hearing  association  (ASHA)  protocols.
Audioprofiles  and  their  median  audiograms  were  used  to
examine  audiological  features.  A  vestibular  test  was
performed  on  all  patients;  evaluation  of  spontaneous  and
evoked  eye  movements  (nystagmus)  and  a  caloric  test
(Fitzgerald-Hallpike)  were  performed  under
electronystagmograpic registration. All patients underwent
neuro-imaging with high-resolution MRI to exclude brain and
inner ear malformations. All clinical data was collected in a
patient database and was periodically updated at control visits.
This study was approved by the ethics committee, followed
the Tenets of the Declaration of Helsinki and written consent
for  genetic  testing  was  obtained  from  adult  probands  or
parents of minor patients.
Molecular analysis: Each patient’s genomic DNA, extracted
from peripheral blood according to standard protocols, was
PCR amplified; amplicons from nine Usher genes were used
in  the  primer  extension  reaction  (APEX)  on  the  Usher
genotyping microarray [25-27]. The test on that chip was
intended  to  screen  612  mutations  in  the  genes  MYO7A,
Harmonin,  CDH23,PCDH15,SANS,USH2A,VLGR1,
Whirlin,  and  USH3A.  These  genes  involve  mutations  in
patients  with
USH1B,USH1C,USH1D,USH1F,USH1G,USH2A,USH2C,U
SH2D, and USH3A subtypes. Mutations included in the chip
have previously been described in the literature on Usher
syndrome, and they largely refer to Caucasian populations.
Microarray  containing  hundreds  of  DNA  markers  in  an
ordered  array  allows  the  simultaneous  analysis  of  these
genetic  markers.  APEX  is  a  resequencing  method  for
identification  of  established  mutations.  Oligonucleotide
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with the 5′ end immobilized on the glass slide and the 3′ end
immediately adjacent to the variable site. The DNA chips
were imaged with the Genorama™ QuattroImager (Asper
Biotech, Tartu, Estonia), measuring the fluorescence intensity
for each spot, and the sequence variants identified by specific
software [28-30]. Each probe lies in a specific position on the
DNA-chip;  the  fluorescence  signal  corresponding  to  each
probe is specific for the wild-type or mutant nucleotide. Each
mutation/polymorphism  was  identified  on  an  Usher
microarray by two unique oligomers, which was specifically
designed according to the wild-type sequence of the Usher
genes.
Sanger sequencing: To confirm the results, array-identified
genetic  variants  were  validated  by  direct  sequencing,
performed in the two centers enrolled in the study (Trieste and
Napoli, Italy), using standard protocols. The fragments were
resolved  on  an  ABI  PRISM®  3700  Genetic  Analyzer
(Applied Biosystems, Carlsbad, CA), automated sequencer.
Wherever  possible,  segregation  of  the  mutated  allele  was
assessed (in 9 out of 25 positive cases) by Sanger sequencing
(see above).
RESULTS
Twenty-five  patients  with  Usher  syndrome  out  of  the  75
analyzed (33%) were found to be positive for the presence of
pathogenic mutations using the Asper chip. Among these,
three  patients  were  positive  for  the  presence  of  one
homozygous  mutation,  six  patients  were  positive  for  the
presence of two mutations (heterozygous composite), and 15
patients were positive for the presence of one mutated allele,
while one patient was positive for the presence of one mutated
allele in two different genes, CDH23 and PCDH15. All the
remaining cases were completely negative for the presence of
mutations (see Figure 1).
The entire detection allele rate was 22.6% (34 pathologic
alleles out of 150), and the following genes were positive (see
also Table 1) in a decreasing order of relevance: USH2A (27
alleles),  CDH23  (3  alleles),  MYO7A  (2  alleles),  and
PCDH15 (2 alleles).
The  genotyping  microarray  identified  15  different
variants  in  USH2A:  of  these,  the  c.1663C>G  (p.L555V)
variation, previously reported to be a pathogenic variant, is
unlikely to represent a mutation, at least in patients 115 and
319 (Table 1). In fact, the c.1663C>G (p.L555V) variation
was  present  in  cases  in  which  two  clearly  pathogenetic
mutations were already present; in particular, the c.1663C>G
(p.L555V)  allele  was  in  cis  with  c.187C>T  (p.R63X)
nonsense mutation in one case.
Mutation c.3178C>T in the CDH23 gene (patient 120),
which corresponded to a protein variation p.R1060W, was
classified as “probably non pathologic” by experimental data
[31],  as  well  as  mutation  c.905G>A  (p.R302H)  in  the
MYO7A gene (patient 125), which has been reported as not
being directly responsible for USH1B phenotype since it has
only a minor effect on the motor activity of myosin VIIa
[32].
Finally, mutation c.3625A>G in the CDH23 gene (patient
117) corresponded to a protein variation p.T1209A, and was
predicted as a “benign” non pathogenic allele by PolyPhen2.
According  to  the  clinical  classification  of  patients,
pathologic variants were detected in two out of seven patients
with Usher syndrome type 1 (28.5%), seven out of 39 patients
with Usher syndrome type 2 (18%), and 16 out of 29 patients
with unclassified Usher syndrome (55.1%). The mutations in
the  USH2A  gene,  c.11864G>A  (p.W3955X),  c.2299delG
(p.E767fs), c. 1547G>T (p.G516V) were found with a slightly
increased frequency in the Italian population, followed by
mutations c.1841–2A>G, c.921_922insCAGC (dupGCCA)
(p.H308Fs),  c.  3368A>G  (p.Y1123C),  and  c.2137G>C
(p.G713R). Moreover, in one case, heterozygous mutations
were detected in two different genes, CDH23 and PCDH15;
findings  compatible  with  a  possible  case  of  digenic
inheritance [33]. In this last case, as well as in an additional
eight positive cases, segregation analysis was performed to
confirm the presence of two independent mutations.
DISCUSSION
Identification of causal mutations is important for the early
diagnosis  of  Usher  syndrome,  which  is  relevant  for  the
decision  regarding  whether  or  not  to  elect  for  a  cochlear
Figure  1.  The  percentage  of  positive
cases  obtained  from  the  molecular
screening of the entire series of Italian
Usher cases. The chart shows the results
of the molecular screening for usherin
(USH2A); protocaderhin 15 (PCDH15);
cadherin  23  (CDH23);  myosin  VIIA
(MYO7A); and the absence of mutated
alleles (NONE).
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.implant, for genetic counseling, and prenatal diagnosis. We
have described the results of a mutation screening using one
of the most up-to-date technologies for a large set of Usher
syndrome cases in Italy.
The overall mutation detection rate was 33.3%, including
cases positive for the presence of only one mutated allele. This
percentage is almost identical to that recently reported for a
set  of  183  Spanish  patients,  where  the  overall  mutation
detection rate was 33.9% [31]. Our data, together with data
obtained  in  the  Spanish  study,  suggest  that  the  mutation
detection rate for the Mediterranean area is probably lower
than that reported in other countries when the chip is used
[27]. There are several explanations for this finding and they
will be discussed later.
One patient was found to be compound heterozygous for
mutations in two different genes, one in PCDH15 and the
other in CDH23; since proteins interact with one another and
form  dynamic  protein  complexes,  digenic  or  oligogenic
inheritance of Usher syndrome is not surprising. Indications
for digenic inheritance involving mutations in the PCDH15
and CDH23 genes have already been obtained in both mice
and in human patients [33].
Despite its obvious advantages in terms of rapidity, the
current genotyping microarray chip shows some limitations
in detecting insertions or deletions; some of the nucleotide
variation  included  in  the  chip  does  not  have  a  clearly
established  pathological  implication  and  needs  to  be
improved;  finally,  the  current  chip  is  only  useful  for  the
detection of previously identified mutations.
In  conclusion,  our  data  clearly  indicate  that  a)  more
accurate technologies such as target(s) re-sequencing will be
needed for final diagnosis, while genotyping microarray is a
robust, low-cost, and rapid technique that is effective for the
genetic study of patients with Usher syndrome, b) the array is
able to detect variants of an unclear pathologic nature and
detection failures have also been observed, c) the results must
be confirmed by direct sequencing to avoid misdiagnosis,
while  continual  updates  of  the  microarray  should  be
performed to increase the efficiency and rate of mutation
detection. Moreover, the low mutation detection rate in both
Italy and Spain [31], might suggest either the presence of
many private or population-specific mutations not included in
the chip/array, or might refer to the presence of additional
putative  and  as  yet,  unidentified  Usher  syndrome  genes,
which  further  increases  the  genetic  heterogeneity  of  this
syndrome.
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